[go: up one dir, main page]

NO20005151L - Substituerte indoliner med en inhiberende effekt pÕ kinaser og cyclin/CDK komplekser - Google Patents

Substituerte indoliner med en inhiberende effekt pÕ kinaser og cyclin/CDK komplekser

Info

Publication number
NO20005151L
NO20005151L NO20005151A NO20005151A NO20005151L NO 20005151 L NO20005151 L NO 20005151L NO 20005151 A NO20005151 A NO 20005151A NO 20005151 A NO20005151 A NO 20005151A NO 20005151 L NO20005151 L NO 20005151L
Authority
NO
Norway
Prior art keywords
cyclin
kinases
inhibitory effect
cdk complexes
substituted indolines
Prior art date
Application number
NO20005151A
Other languages
English (en)
Other versions
NO317298B1 (no
NO20005151D0 (no
Inventor
Armin Heckel
Rainer Walter
Wolfgang Gress
Jacobus C A Van Meel
Norbert Redemann
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20005151L publication Critical patent/NO20005151L/no
Publication of NO20005151D0 publication Critical patent/NO20005151D0/no
Publication of NO317298B1 publication Critical patent/NO317298B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20005151A 1998-04-15 2000-10-13 Substituerte indoliner med en inhiberende effekt pa kinaser og cyclin/CDK komplekser NO317298B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19816624A DE19816624A1 (de) 1998-04-15 1998-04-15 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP1999/002436 WO1999052869A1 (de) 1998-04-15 1999-04-10 Substituierte indolinone mit inhibierender wirkung auf kinasen und cyclin/cdk-komplexe

Publications (3)

Publication Number Publication Date
NO20005151L true NO20005151L (no) 2000-10-13
NO20005151D0 NO20005151D0 (no) 2000-10-13
NO317298B1 NO317298B1 (no) 2004-10-04

Family

ID=7864562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005151A NO317298B1 (no) 1998-04-15 2000-10-13 Substituerte indoliner med en inhiberende effekt pa kinaser og cyclin/CDK komplekser

Country Status (31)

Country Link
EP (1) EP1071665B1 (no)
JP (1) JP4015365B2 (no)
KR (1) KR100588250B1 (no)
CN (1) CN100338036C (no)
AR (1) AR015763A1 (no)
AT (1) ATE251138T1 (no)
AU (1) AU749829B2 (no)
BG (1) BG64443B1 (no)
BR (1) BR9909688A (no)
CA (1) CA2323111C (no)
CO (1) CO5011040A1 (no)
DE (2) DE19816624A1 (no)
DK (1) DK1071665T3 (no)
EA (1) EA003532B1 (no)
EE (1) EE04432B1 (no)
ES (1) ES2207209T3 (no)
HU (1) HUP0101568A3 (no)
ID (1) ID26420A (no)
IL (1) IL138036A0 (no)
MY (1) MY122357A (no)
NO (1) NO317298B1 (no)
NZ (1) NZ507967A (no)
PL (1) PL343314A1 (no)
PT (1) PT1071665E (no)
SK (1) SK283824B6 (no)
TR (1) TR200002980T2 (no)
TW (1) TW510897B (no)
UA (1) UA63009C2 (no)
WO (1) WO1999052869A1 (no)
YU (1) YU59800A (no)
ZA (1) ZA200004623B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
DE19924401A1 (de) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2257313T3 (es) 1999-08-27 2006-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Indolinonas sustituidas en calidad de inhibidores de tirosina quinasa.
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
RS50444B (sr) 2000-02-15 2010-03-02 Sugen Inc. Inhibitori 2-indolinon protein kinaze supstituisani pirolom
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2003082280A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
JP4949845B2 (ja) 2003-10-03 2012-06-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼインヒビター結合アッセイにおける使用のための蛍光プローブ
DE102004012070A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2592514A1 (en) 2004-12-27 2006-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2611401C (en) * 2005-06-10 2014-02-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Oxindoles as kinase inhibitors
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
KR20090097908A (ko) 2006-12-06 2009-09-16 베링거 인겔하임 인터내셔날 게엠베하 글루코코르티코이드 모사물, 이의 제조 방법, 이의 약제학적 조성물 및 용도
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
CN102112476A (zh) 2008-06-06 2011-06-29 贝林格尔.英格海姆国际有限公司 糖皮质激素模拟物、其制备方法、药物组合物及其用途
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
JP6072058B2 (ja) 2011-11-14 2017-02-01 リガンド・ファーマシューティカルズ・インコーポレイテッド 顆粒球コロニー刺激因子受容体と結合する方法および組成物
US9962370B2 (en) * 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN107033064B (zh) * 2017-04-28 2019-07-09 西安医学院 一种3-(吗啉取代芳亚胺基)吲哚类化合物及其制备方法和应用
CN111285872B (zh) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 吲哚-2-酮衍生物及其制备方法与用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу

Also Published As

Publication number Publication date
TW510897B (en) 2002-11-21
EE04432B1 (et) 2005-02-15
TR200002980T2 (tr) 2001-02-21
CA2323111A1 (en) 1999-10-21
CN1297438A (zh) 2001-05-30
JP2002511449A (ja) 2002-04-16
ZA200004623B (en) 2001-05-30
HUP0101568A3 (en) 2002-12-28
SK15132000A3 (sk) 2001-03-12
AU3814999A (en) 1999-11-01
BG64443B1 (en) 2005-02-28
WO1999052869A1 (de) 1999-10-21
JP4015365B2 (ja) 2007-11-28
CN100338036C (zh) 2007-09-19
YU59800A (sh) 2003-04-30
DK1071665T3 (da) 2004-01-05
EP1071665B1 (de) 2003-10-01
DE19816624A1 (de) 1999-10-21
EA200001021A1 (ru) 2001-06-25
AR015763A1 (es) 2001-05-16
ID26420A (id) 2000-12-21
NZ507967A (en) 2003-04-29
DE59907199D1 (de) 2003-11-06
ATE251138T1 (de) 2003-10-15
EP1071665A1 (de) 2001-01-31
ES2207209T3 (es) 2004-05-16
PT1071665E (pt) 2004-02-27
BR9909688A (pt) 2000-12-19
KR20010042731A (ko) 2001-05-25
BG104813A (bg) 2001-08-31
HUP0101568A2 (hu) 2001-09-28
IL138036A0 (en) 2001-10-31
KR100588250B1 (ko) 2006-06-13
NO317298B1 (no) 2004-10-04
MY122357A (en) 2006-04-29
SK283824B6 (sk) 2004-02-03
CA2323111C (en) 2009-09-15
CO5011040A1 (es) 2001-02-28
EE200000598A (et) 2002-04-15
UA63009C2 (en) 2004-01-15
EA003532B1 (ru) 2003-06-26
AU749829B2 (en) 2002-07-04
NO20005151D0 (no) 2000-10-13
PL343314A1 (en) 2001-08-13

Similar Documents

Publication Publication Date Title
NO20005151L (no) Substituerte indoliner med en inhiberende effekt pÕ kinaser og cyclin/CDK komplekser
NO20011477D0 (no) Nye substituerte indolinoner med inhiberende virkning pÕ forskjellige kinaser og cyclin/CDK-komplekser
NO20015045D0 (no) Diaminotiazoler og deres anvendelse til inhibering av proteinkinaser
NO20014659L (no) Arylsubstituerte pyrazoler, imidazoler, oksazoler, tiazoler og pyrroler samt deres anvendelse
ATE292140T1 (de) N6 heterocyclische 8-modifizierte adenosinderivate
NO20014114D0 (no) 4-Amino-kinazolin- og -kinolin-derivater med inhiberende virkning pa signaltransduksjon mediert ved tyrosin-kinaser
DK1117669T3 (da) Antiviruspurinderivater
ATE277941T1 (de) Adenosinderivate
NO991150D0 (no) Pyrazolopyrimidiner og pyrazolotriaziner
PT900210E (pt) Derivados azahexano heterociclicos com actividade antviral
DK1104422T3 (da) Phenylxanthinderivater
NO980718D0 (no) Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer
NO990053D0 (no) Fresstyring med orienterings- og dybdebestemmelsesevne
NO986174L (no) Triazinderivater og anvendelse derav
NO20012606D0 (no) Forbindelse med inhibitorisk virkning på kolesteryloverförende protein samt fremstilling derav
MX9201635A (es) Derivados de indol y di hidro quinolina.
SI1071665T1 (sl) Substituirani indolinoni, ki imajo inhibitorni učinek na kinaze in ciklin/CDK komplekse
ATE250025T1 (de) Hydrazin-derivate
ES1035703Y (es) Tapon perfeccionado.
ES1042708Y (es) Tapon corona perfeccionado.
FI990830A0 (fi) Elektroniikka- ja instrumentointikotelo
ES1039353Y (es) Tapon perfeccionado.
ES1033292Y (es) Tapon perfeccionado.
ES1039069Y (es) Tapon perfeccionado.
ES1043985Y (es) Tapon perfeccionado.